Following a particularly well received first phase of their clinical pilot program, medical technology company 4DMedical (ASX: 4DX) is advancing their respiratory imaging platform to Phase 2 of their clinical pilot program.
Conducted with Australia’s leading medical imaging provider, I-MED Radiology Network, Phase 1 of the program saw radiologists use 4DMedical’s proprietary XV Lung Ventilation Analysis Software (XV LVAS™) to gather insights into patient care. I-MED specialist thoracic radiologists reviewed and utilised XV LVAS™ as part of their clinical workflow to further improve program insights.
Established innovator, Dr. Andreas Fouras sits at the helm of 4DMedical. Born out of his research group at Monash University, 4DMedical’s tech images the lung’s motion in four dimensions (hence the name, 4D), allowing for better insight into lung function.
With clinical trials underway at several locations across the US, the TGA and FDA approved tech is being validated through clinical pilot evaluations which allow clinicians to use and evaluate the usability of the tech in everyday practice.
4DMedical’s software is capable of leveraging existing imaging infrastructure to offer more comprehensive insights into lung diagnostics. They also have created a specialised XVD scanner, with their XV LVAS™ software as standard.
Several disease indications were analysed during the I-MED program including asthma, chronic obstructive pulmonary disease (COPD) and long term symptoms following COVID infection.
Looking to further validate their tech, the Company will now progress to Phase Two of their pilot program with I-MED. This Phase will see additional radiologists utilise the XV LVAS™.
The pilot program represents a significant potential commercial opportunity for 4DMedical, with I-MED as Australia’s largest outsourced provider of radiology and imaging services across 200 clinics nationwide.
CEO and Founder, Dr. Andreas Fouras said: “We are very excited to be conducting a clinical pilot with I-MED- a leader of pioneering new medical imaging technologies- to provide doctors and patients with improved insight into their lung health. Phase One of the clinical pilot was an overwhelming success with radiologists and patients reporting strong positive feedback. Although the partnership is not generating revenue at this stage, we aim to secure a commercial XV LVAS™ contract with I-MED provided that Phase Two is successful.”
Phase 2 of the clinical pilot will be carried out over the remainder of the year to further assess a potential commercial partnership, having confirmed the XV LVAS™ compatibility with I-MED’s existing infrastructure.
In their FY21 results the Company reported a cash balance of $80.9 million with no debt, positioning them well to continue exploring commercial agreements and partnerships as well as seeing clinical trials to completion.
*The author of this article is a 4DX shareholder
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
- Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
- How this company is developing medtech to support Indigenous community health - August 22, 2022
- A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022
Leave a Comment
You must be logged in to post a comment.